Plus Therapeutics (PSTV) Reports Break-Even Earnings for Q4
Plus (PSTV) delivered earnings and revenue surprises of +100.00% and +2.02%, respectively, for the quarter ended December 2025. Do the…
0,157$
-3,68%
Echtzeit-Aktienkurs Plus Therapeutics Inc.
Bid:
Ask:
Nachrichten zur Plus Therapeutics Inc. Aktie
Plus Therapeutics Reports 2025 Results, Business Progress and 2026 Anticipated Milestones for REYOBIQ™ Clinical Program and CNSide® Commercial Rollout
HOUSTON, March 12, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a healthcare…
InterAx und Alveus kündigen strategische Forschungs- und Lizenzvereinbarung zur Entwicklung eines differenzierten therapeutischen Arzneimittelkandidaten für Stoffwechselerkrankungen an
ZÜRICH, PHILADELPHIA UND KOPENHAGEN, Dänemark--(BUSINESS WIRE)--InterAx Biotech Ltd („InterAx“) und Alveus Therapeutics Inc. („Alveus“) haben heute eine strategische Forschungskooperation und…
HLS Therapeutics Inc. (HLS:CA) Q3 2025 Earnings Call Transcript
…
HLS Therapeutics Inc. 2025 Q3 - Results - Earnings Call Presentation
…
Plus Therapeutics (PSTV) Reports Q3 Loss, Lags Revenue Estimates
Plus (PSTV) delivered earnings and revenue surprises of -100.00% and -36.79%, respectively, for the quarter ended September 2025. Do the…
Plus Therapeutics (PSTV) Reports Q1 Loss, Misses Revenue Estimates
Plus (PSTV) delivered earnings and revenue surprises of -229.41% and 42.76%, respectively, for the quarter ended March 2025. Do the…
Plus Therapeutics (PSTV) Reports Q4 Loss, Misses Revenue Estimates
Plus (PSTV) delivered earnings and revenue surprises of -31.37% and 6.49%, respectively, for the quarter ended December 2024. Do the…
PSTV Stock Surges as FDA Accepts Proprietary Name for Lead Drug
The FDA conditionally accepts Plus Therapeutics new proprietary name, Reyobiq, for its lead therapeutic candidate. Stock shoots up.…
PSTV Stock Skyrockets on FDAs Orphan Drug Tag for Cancer Therapy
The FDA bestows an Orphan Drug tag to Plus Therapeutics investigational drug, rhenium (186Re) obisbemeda, for treating leptomeningeal metastases in…
Plus Therapeutics to Showcase ReSPECT-LM Phase 1 Interim Data for Leptomeningeal Metastases at the 2024 San Antonio Breast Cancer Symposium
Plus Therapeutics to Showcase ReSPECT-LM Phase 1 Interim Data for Leptomeningeal Metastases at the 2024 San Antonio Breast Cancer Symposium…
Plus Therapeutics, Inc. (PSTV) Q3 2024 Earnings Call Transcript
…
Plus Therapeutics and SpectronRx Announce Radiotherapeutic Manufacturing Partnership
Plus Therapeutics and SpectronRx Announce Radiotherapeutic Manufacturing Partnership…
Plus Therapeutics granted extension by Nasdaq By Investing.com
Plus Therapeutics granted extension by Nasdaq…
Plus Therapeutics, Inc. (PSTV) Q2 2024 Earnings Call Transcript
…
Plus Therapeutics, Inc. (PSTV) Q1 2024 Earnings Call Transcript
…
Plus Therapeutics, Inc. (PSTV) Q4 2023 Earnings Call Transcript
…